Levemir InnoLet DHPC Letter: What Pharmacists Need to Know
Quick summary The DHPC letter states that Levemir® InnoLet® is being discontinued, with a stated date of May 2024. The letter advises healthcare professionals to consider alternative delivery options and to monitor blood glucose...
This content is for educational purposes only and does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.
Quick summary
The DHPC letter states that Levemir® InnoLet® is being discontinued, with a stated date of May 2024. The letter advises healthcare professionals to consider alternative delivery options and to monitor blood glucose closely during any transition.
Medical disclaimer: This article is for general information only and does not replace the product leaflet, local guidance, or advice from a qualified healthcare professional. Do not make changes to diabetes treatment without clinical review.
What the DHPC letter says
The current content indicates that a DHPC letter was issued about Levemir® InnoLet® 100 units/ml solution for injection in pre-filled pen. The key message is that the product will be discontinued by May 2024.
For pharmacists and other healthcare professionals, the practical implication is to identify patients using this device, check supply arrangements, and support a planned transition where needed.
Why this matters in practice
When an insulin device is discontinued, patients may need a different presentation or delivery system even if the active ingredient remains familiar. The original content highlights the importance of:
- informing patients about the change,
- monitoring blood glucose closely during transition, and
- reviewing alternative insulin devices or products with the prescriber.
Any switch should be handled carefully, with attention to the patient’s current regimen and the instructions in the official product information.
Alternatives mentioned in the source content
The original article names Levemir® FlexPen® and Levemir® Penfill® as alternatives to consider. It also mentions other insulin options that may be suitable in some treatment plans, including:
- insulin glargine (Lantus®),
- insulin degludec (Tresiba®),
- insulin detemir in other devices.
Which option is appropriate depends on the individual patient, the prescriber’s decision, and the official prescribing information.
What is Insulatard® InnoLet®?
The source content also discusses Insulatard® InnoLet®. It describes this as a pre-filled pen used for insulin administration and notes that it is an intermediate-acting insulin.
The article states that it is given by subcutaneous injection and is used in diabetes management. It also notes that it may be used once or twice daily depending on individual needs.
Key features highlighted in the original content
According to the source material, Insulatard® InnoLet® is described as having the following features:
- pre-filled pen format for convenient use,
- designed for subcutaneous injection,
- intended to support accurate insulin delivery,
- described as stable at room temperature in the original content.
Readers should confirm all handling and storage details in the official leaflet or local product information.
Administration points mentioned in the source
The original content says Insulatard® InnoLet® should be injected subcutaneously into areas such as the abdomen, thigh, or upper arm.
It also notes the importance of rotating injection sites to help reduce the risk of lipodystrophy. Consistent timing of administration is described as important for blood glucose control.
Warnings and monitoring
The source content highlights the need to watch for both hyperglycemia and hypoglycemia. It also stresses regular blood glucose monitoring, especially when treatment is being adjusted or when a patient is moving to a different device.
The article additionally mentions the MHRA Yellow Card scheme as a route for reporting suspected side effects or product concerns.
Practical checklist for pharmacists
| Topic | What to verify |
|---|---|
| Product status | Confirm the discontinuation message and timing in official communications. |
| Patient supply | Check whether the patient is using Levemir® InnoLet® and whether a replacement device is needed. |
| Transition support | Review the prescriber’s plan and reinforce blood glucose monitoring. |
| Device counselling | Confirm injection technique, site rotation, and leaflet instructions for the chosen product. |
Frequently asked questions
▸ Is Levemir InnoLet being discontinued?
Yes. The source content states that Levemir® InnoLet® is to be discontinued by May 2024.
▸ What alternatives are mentioned?
The article mentions Levemir® FlexPen® and Levemir® Penfill® as alternatives to consider, along with other insulin options that may be suitable in some cases.
▸ What type of insulin is Insulatard InnoLet?
The original content describes Insulatard® InnoLet® as an intermediate-acting insulin.
▸ How is Insulatard InnoLet administered?
It is described as a subcutaneous injection, with sites including the abdomen, thigh, or upper arm.
▸ What should be monitored during a switch?
The source content emphasizes close blood glucose monitoring during any transition to help reduce the risk of poor glycemic control.
▸ Where can suspected side effects be reported?
The article mentions the MHRA Yellow Card scheme as the reporting route for suspected side effects or product concerns.
Safety reminder: Always check the latest official product information, DHPC communication, and local guidance before dispensing or counselling. If a patient’s insulin device changes, ensure the prescriber’s plan is followed and blood glucose is monitored appropriately.
Sources to verify
The original content refers to a DHPC letter, MHRA reporting, and Novo Nordisk product information. For accuracy, readers should verify details against the official DHPC, the current Summary of Product Characteristics, and local medicines guidance.
Medical disclaimer
This content is for educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Always ask a doctor, pharmacist or qualified healthcare professional before starting, stopping or changing any medicine.
Sources and verification
The following sources or official references are listed to support verification of the medicine information discussed in this article.
Medicine information can change and may vary depending on country, product formulation, patient history and professional guidance. Always check official medicine information and ask a healthcare professional for personal medical questions.